An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder
Sponsor: Janssen Research & Development, LLC
Listed as NCT02473289, this PHASE2 trial focuses on Depressive Disorder, Major and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 17 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Mar 2025 — May 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2018 — Jul 2019 [monthly]
Completed PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jul 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .